|
Earnings Scope: Rockwell Medical, Inc. (NASDAQ:RMTI) - Markets Daily |
 |
|
Sell-side analysts are expecting Rockwell Medical, Inc. (NASDAQ:RMTI) to report quarterly earnings per share of $-0.11 for the quarter ending 2015-06-30. This consensus figure is based on 5 firms providing estimates. Investors will be paying close attention to whether the company misses or beats this number. The company is slated to report earnings on or around 2015-07-30.
Rockwell Medical, Inc. (NASDAQ:RMTI) posted a surprise factor of 30% for the previous quarter where the analyst consensus EPS estimate turned out to be $0.03 away from the reported actual number of $-0.07. Before reporting, the standard deviation stood at $0.05. Predicted Stock Movement Over the next year, covering analysts have a consensus price target on the stock of $16. This number stems from 5 firms that are providing projections on the stock. Out of these analysts, the high projection stands at $26 while the low projection sees the stock at $4 over the next 52 weeks. The standard deviation of the price targets stands at $7.968. Rockwell Medical, Inc. (NASDAQ:RMTI) has a current consensus rating of 1.8. On this scale a one would represent a Strong Buy while a five rating would indicate a Strong Sell. Keeping an eye on the ratings trend, the equity had a three-months ago rating of 1.8. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|